Eli Lilly’s stock reached an all-time high of $1022.62 USD, marking a significant milestone for the pharmaceutical giant. According to InvestingPro data, the company’s RSI suggests the stock is in ...

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive ...

Reports Q3 revenue $410,000 vs. $10.9M last year. “Following the close of the third quarter, we are very pleased to have signed a strategic ...

Lilly will also gain exclusive access to MeiraGTx’s gene therapy platform technologies, including novel intravitreal capsids ...

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing ...

MeiraGTx Holdings plc stock surges after a major Eli Lilly partnership boosts funding and pipeline. Click for my updated look ...

In this week’s edition of InnovationRx, we look at BillionToOne’s IPO, China’s biotech power couple and Lilly’s eye drug deal ...

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives from Novo and Eli Lilly to the White House to announce that the companies’ ...

In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, ...

The company's shares (LLY) climbed 2.3% Tuesday to end at $988.62 a share, after closing at a record high of $966.64 on Monday. The rally has pushed Lilly's market capitalization up to $934.6 billion, ...

Lilly's shares have taken off in the wake of several significant deals and after it received fast-track regulatory review for ...